The GABAB receptor antagonist CGP 36 742 and the nootropic oxiracetam facilitate the formation of long-term memory

Behavioural Brain Research

Volumn 77, Issue 1-2, 1996, Pages 223-225

  Mondadori, Cesare ^a,b   Möbius, Hans Jörg ^a   Borkowski, Jürgen ^a  

^a CIBA GEIGY LTD   (Switzerland)

^b SANOFI   (France)

Author keywords

CGP 36 742; GABAB; Memory; Mouse; Oxiracetam

Indexed keywords

(3 AMINOPROPYL)(N BUTYL)PHOSPHINIC ACID; (3-AMINOPROPYL)(N-BUTYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; ORGANOPHOSPHORUS COMPOUND; OXIRACETAM; PYRROLIDINE DERIVATIVE; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID;

ANIMAL; ARTICLE; BRAIN; DOSE RESPONSE; DRUG EFFECT; FEMALE; LONG TERM POTENTIATION; MOUSE; MOUSE STRAIN; RECALL; ANIMAL EXPERIMENT; BEHAVIOR; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LONG TERM MEMORY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GABA ANTAGONISTS; LONG-TERM POTENTIATION; MENTAL RECALL; MICE; MICE, INBRED STRAINS; NOOTROPIC AGENTS; ORGANOPHOSPHORUS COMPOUNDS; PYRROLIDINES; RECEPTORS, GABA-B;

EID: 0029665060     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-4328(95)00222-7     Document Type: Article

References (12)

1. B blocker improves the cognitive performance of mice, rats and rhesus monkeys. Behav. Neural Biol., 60 (1993) 62-68.
2. B antagonists: potential new drugs. Pharmacol Commun., 2(1992) 70-74.
3. Carletti, R., Libri, V. and Bowery, N.G., The GABAB antagonist, CGP 36742, enhances spatial learning performance and antagonizes baclofen-induced amnesia in mice. Br. J. Pharmacol., 109 (1993) 74P.
4. B antagonist, facilitates memory in a social recognition test in rats. Behav. Brain Res., 77 (1996) 227-229.
5. Mondadori, C., Hengerer, B., Ducret, T. and Borkowski, J., Delayed emergence of effects of memory-enhancing drugs: implications for the dynamics of long-term memory. Proc. Natl. Acad. Sci. USA, 91 (1994) 2041-2045.
6. Mondadori, C., The pharmacology of the nootropics; new insights and new questions. Behav. Brain Res., 59 (1993) 1-9.
7. Cohen, N.J. and Squire, L.R., Preserved learning and retention of a pattern-analyzing skill in amnesia: dissociation of knowing how and knowing that. Science, 210 (1980) 207-210.
8. Fitten, L.J., Perryman, K.M., Gross, P.L., Fine, H., Cummins, J. and Marshall, C., Treatment of Alzheimer's disease with short-and long-term oral THA and lecithin: a double blind study. Am. J. Psychiatry, 147 (1990) 239-242.
9. Molloy, D.W., Standish, T., Bédard, M. et al., Can caregiver identify responders in clinical trials with Alzheimer Patients? (submitted).
10. Dager, S.R., Loebel, J.P., Claypool, K., Case, M., Budech, C.B. and Dunner, D.L., Oxiracetam in the treatment of primary dementia of the alzheimer's type: a small case series. Intern. J. Geriatric Psychiatry, 7 (1992) 905-912.
11. Chouinard, G., Annable, L. and Ross-Chouinard, A., A double-blind placebo-controlled study of piracetam in elderly psychiatric patients. Psychopharmacol. Bull., 17 (1981) 129.
12. Tukey, J.W., Exploratory Data Analysis. London: Addison Wesley, 1977, p. 47.